Safety and efficacy of glecaprevir and pibrentasvir in north Tohoku Japanese patients with genotype 1/2 hepatitis C virus infection

Safety and efficacy of glecaprevir and pibrentasvir in north Tohoku Japanese patients with genotype 1/2 hepatitis C virus infection

Abstract Background and aims To assess the efficacy and safety of treatment with glecaprevir/pibrentasvir in Japanese patients with genotype (GT) 1/2 hepatitis C virus (HCV) infection in a real‐world clinical setting. Methods A total of 230 patients from 12 centers in northern Tohoku Japan with chro...

Full description

Bibliographic Details
Main Authors: Akio Miyasaka, Yuichi Yoshida, Akihiko Murakami, Takao Hoshino, Kei Sawara, Hiroshi Numao, Yasuhiro Takikawa
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Health Science Reports
Subjects:
antiviral agent
chronic kidney disease
hepatitis C virus
sustained virologic response
Online Access:https://doi.org/10.1002/hsr2.458

Similar Items

Similar Items